Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis
- PMID: 37506783
- DOI: 10.1016/j.jep.2023.116967
Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis
Abstract
Ethnopharmacological relevance: Chaihu Shugan powder (CSP) plays an important role in the prevention and treatment of nonalcoholic fatty liver disease (NAFLD) through a variety of biological mechanisms. However, whether the mechanism involves microRNA (miRNA) regulation remains unknown.
Aim of the study: To investigate the effects of CSP on the miRNA expression profile of rats with NAFLD induced by high-fat diet (HFD), and to explore the mechanism of CSP in the treatment of NAFLD.
Methods: NAFLD rat models were established by an 8-week HFD. The therapeutic effects of CSP on NAFLD were evaluated by physiological, biochemical and pathological analysis and hepatic surface microcirculation perfusion test. MicroRNA sequencing was used to study the effect of CSP on the miRNA expression profile of NAFLD rats, and the target genes of differentially expressed (DE) miRNAs were predicted for further function enrichment analysis. Next, targets of CSP and NAFLD were collected by a network pharmacological approach, and Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analysis were performed for the common target genes of CSP, NAFLD and DE miRNAs, and the expression levels of key genes and proteins were verified by quantitative Real-time PCR and Western blot. Finally, a network among formula-herb-compound-miRNA-target-biological processes-disease was established to explained the complex regulation mechanism of CSP on NAFLD.
Results: The results showed that CSP significantly improved liver lipid accumulation, serum lipid and transaminase levels and liver surface microcirculation disturbance in HFD-induced NAFLD rats. The intervention of CSP reversed the high expression of 15 miRNAs in liver tissues induced by HFD, including miR-34a-5p, miR-146a-5p, miR-20b-5p and miR-142-3p. The results of pathway and functional enrichment analysis showed that, CSP might play an anti-NAFLD role via regulating DE miRNAs related to fatty acid metabolic process. Combined with the network pharmacological analysis, it was found that the DE miRNAs might affected the fatty acid biosynthesis pathway in the treatment of NAFLD by CSP. Molecular biology experiments have conformed the decreased the gene and protein levels of acetyl-CoA carboxylase alpha (ACACA), fatty acid synthase (FASN) and other fatty acid biosynthesis related enzymes on NAFLD rats after intervention of CSP.
Conclusions: CSP can significantly reduce hepatic lipid accumulation of NAFLD rat model induced by HFD, and its mechanism may be through the action of 15 miRNAs such as miR-34a-5p, miR-146a-5p, miR-20b-5p and miR-142-3p. Reduce the gene and protein expression levels of ACACA, FASN and other fatty acid biosynthesis related enzymes, thus reducing fatty acid biosynthesis. Based on an epigenetic perspective, this study explains the key anti-NAFLD mechanism of CSP via combination of microRNA sequencing and network pharmacological analysis, providing a new reference for the modernization of traditional Chinese medicine.
Keywords: Chaihu Shugan powder; Fatty acid biosynthesis; Network pharmacology; Nonalcoholic fatty liver disease; microRNA.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors.J Cell Mol Med. 2020 May;24(9):5168-5184. doi: 10.1111/jcmm.15166. Epub 2020 Mar 18. J Cell Mol Med. 2020. PMID: 32189432 Free PMC article.
-
Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: A network pharmacology study and in vivo experimental validation.Front Pharmacol. 2022 Sep 12;13:967623. doi: 10.3389/fphar.2022.967623. eCollection 2022. Front Pharmacol. 2022. PMID: 36172180 Free PMC article.
-
Gan-Jiang-Ling-Zhu decoction alleviates hepatic steatosis in rats by the miR-138-5p/CPT1B axis.Biomed Pharmacother. 2020 Jul;127:110127. doi: 10.1016/j.biopha.2020.110127. Epub 2020 Apr 20. Biomed Pharmacother. 2020. PMID: 32325349
-
MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.Mol Metab. 2022 Nov;65:101581. doi: 10.1016/j.molmet.2022.101581. Epub 2022 Aug 23. Mol Metab. 2022. PMID: 36028120 Free PMC article. Review.
-
Network pharmacology-based identification of miRNA expression of Astragalus membranaceus in the treatment of diabetic nephropathy.Medicine (Baltimore). 2022 Feb 4;101(5):e28747. doi: 10.1097/MD.0000000000028747. Medicine (Baltimore). 2022. PMID: 35119030 Free PMC article.
Cited by
-
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies.Chin Med. 2024 Feb 3;19(1):21. doi: 10.1186/s13020-024-00894-1. Chin Med. 2024. PMID: 38310315 Free PMC article. Review.
-
Innovative approaches to metabolic dysfunction-associated steatohepatitis diagnosis and stratification.Noncoding RNA Res. 2024 Oct 11;10:206-222. doi: 10.1016/j.ncrna.2024.10.002. eCollection 2025 Feb. Noncoding RNA Res. 2024. PMID: 40248839 Free PMC article.
-
Chaihu-Shugan-San for patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis.Medicine (Baltimore). 2025 May 2;104(18):e42303. doi: 10.1097/MD.0000000000042303. Medicine (Baltimore). 2025. PMID: 40324244 Free PMC article.
-
Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice.Front Med (Lausanne). 2024 Oct 8;11:1476419. doi: 10.3389/fmed.2024.1476419. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39440040 Free PMC article. Review.
-
Xietu Hemu Prescription Improves Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Cohort Study.J Multidiscip Healthc. 2025 Jul 29;18:4377-4389. doi: 10.2147/JMDH.S522519. eCollection 2025. J Multidiscip Healthc. 2025. PMID: 40756613 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous